Drug intelligence / Profile preview

HDM4002

Development stage: Preclinical
Lead developer: Huadong Medicine
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

HDM4002 is a first-in-class bispecific antibody injection being developed by Huadong Medicine for the treatment of IgA nephropathy. The drug is currently in the IND-enabling development phase, with the company planning to complete IND submissions in both China and the United States by the third quarter of 2026. HDM4002 was discovered and designed using Huadong Medicine's proprietary target discovery platform and artificial intelligence drug design (AIDD) approaches. While the specific molecular targets of this bispecific antibody have not been publicly disclosed, it represents a significant component of the company's strategic focus on autoimmune therapeutic areas and has received government funding support for its development.

Beyond the preview

Go deeper on HDM4002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HDM4002.

Explore the full profile